267 related articles for article (PubMed ID: 26564323)
1. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.
Herrmann K; Schottelius M; Lapa C; Osl T; Poschenrieder A; Hänscheid H; Lückerath K; Schreder M; Bluemel C; Knott M; Keller U; Schirbel A; Samnick S; Lassmann M; Kropf S; Buck AK; Einsele H; Wester HJ; Knop S
J Nucl Med; 2016 Feb; 57(2):248-51. PubMed ID: 26564323
[TBL] [Abstract][Full Text] [Related]
2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
3. [
Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
[No Abstract] [Full Text] [Related]
4. Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.
Maurer S; Herhaus P; Lippenmeyer R; Hänscheid H; Kircher M; Schirbel A; Maurer HC; Buck AK; Wester HJ; Einsele H; Grigoleit GU; Keller U; Lapa C
J Nucl Med; 2019 Oct; 60(10):1399-1405. PubMed ID: 30850502
[TBL] [Abstract][Full Text] [Related]
5. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
Chen Z; Xue Q; Yao S
Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted theranostics in oncology.
Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
[TBL] [Abstract][Full Text] [Related]
8. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
Yang Q; Zhang F; Hao Z; Zhuang J; Huo L
Clin Nucl Med; 2024 Jun; 49(6):592-593. PubMed ID: 38630995
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
11. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.
Lapa C; Herrmann K; Schirbel A; Hänscheid H; Lückerath K; Schottelius M; Kircher M; Werner RA; Schreder M; Samnick S; Kropf S; Knop S; Buck AK; Einsele H; Wester HJ; Kortüm KM
Theranostics; 2017; 7(6):1589-1597. PubMed ID: 28529638
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
13. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.
Mesguich C; Zanotti-Fregonara P; Hindié E
Theranostics; 2016; 6(2):287-90. PubMed ID: 26877786
[TBL] [Abstract][Full Text] [Related]
14. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
Hartlapp I; Hartrampf PE; Serfling SE; Wild V; Weich A; Rasche L; Roth S; Rosenwald A; Mihatsch PW; Hendricks A; Wiegering A; Wiegering V; Hänscheid H; Schirbel A; Werner RA; Buck AK; Wester HJ; Einsele H; Kunzmann V; Lapa C; Kortüm KM
J Nucl Med; 2023 Sep; 64(9):1424-1430. PubMed ID: 37348915
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary Relapsed Multiple Myeloma Treatment With 177Lu-Labeled CXCR4 Endoradiotherapy and Dosimetric Results.
Demirkol MO; Özkan A; Uçar B; Wester HJ; Ferhanoğlu B
Clin Nucl Med; 2021 Aug; 46(8):656-658. PubMed ID: 34034308
[TBL] [Abstract][Full Text] [Related]
16. Biokinetics and Dosimetry of
Hänscheid H; Schirbel A; Hartrampf P; Kraus S; Werner RA; Einsele H; Wester HJ; Lassmann M; Kortüm M; Buck AK
J Nucl Med; 2022 May; 63(5):754-760. PubMed ID: 34413147
[TBL] [Abstract][Full Text] [Related]
17. Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
Martin S; Viertl D; Janz A; Habringer S; Keller U; Schottelius M
EJNMMI Res; 2023 May; 13(1):40. PubMed ID: 37162652
[TBL] [Abstract][Full Text] [Related]
18. First
Poschenrieder A; Osl T; Schottelius M; Hoffmann F; Wirtz M; Schwaiger M; Wester HJ
Tomography; 2016 Jun; 2(2):85-93. PubMed ID: 30042959
[TBL] [Abstract][Full Text] [Related]
19. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.
Luyten K; Van Loy T; Cawthorne C; Deroose CM; Schols D; Bormans G; Cleeren F
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683912
[TBL] [Abstract][Full Text] [Related]
20. Chemokine receptor - Directed imaging and therapy.
Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
